Wei Tu, Queen's University

Research

biostatistics cancer clinical trials censored data functional data analysis functional regression missing data quality of life robust statistic

Latest papers

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).
Cancer treatment and research communications · 2026
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
EClinicalMedicine · 2025
The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.
Current oncology (Toronto, Ont.) · 2025

All 8 publications

Latest funding

Statistical Learning and Inference for Sparse and Heterogeneous Functional and Longitudinal Data
NSERC · 2023 · Principal investigator
$54,000
Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative (Radio)Therapy: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
CIHR · 2023 · Co-investigator
$1,602,675
Statistical Learning and Inference for Sparse and Heterogeneous Functional and Longitudinal Data
NSERC · 2023 · Principal investigator
$12,500

All 5 grants and awards

8 publications.

01

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

MacKay HJ, Tinker AV, Nelson BH, Zamarin D, Odunsi AO, Lheureux S, Ellard S, Smrke A, Gaudreau PO, Faulkner T, Upadhaya S, Zhou A, Tu W, Dancey J

Cancer treatment and research communications2026

DOI: 10.1016/j.ctarc.2026.101260 PMID: 42225005

02

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial

Gupta AA, Tinker A, Jonker D, Jamal R, Hirte H, Winquist EW, Chu Q, Kollmannsberger C, Wong R, Alcindor T

EClinicalMedicine20255 citations

DOI: 10.1016/j.eclinm.2024.102991

03

The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.

Carlson LE, Richardson H, Shore R, Albertyn CP, Balneaves LG, Bates A, Burnell M, Chochinov HM, Clements D, Deleemans J, Horlock H, Mathews J, McKenzie M, Savard C, Soares CN, Tu W, Williams M

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol33010007 PMID: 41590327

04

Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]”

Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M

Journal of Thoracic Oncology2024

DOI: 10.1016/j.jtho.2024.08.017

05

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A

The Lancet2023120 citations

DOI: 10.1016/s0140-6736(23)01613-6

06

Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M

Journal of Thoracic Oncology202323 citations

DOI: 10.1016/j.jtho.2023.02.003

07

Low-Rank Plus Sparse Decomposition of fMRI Data With Application to Alzheimer's Disease.

Tu W, Fu F, Kong L, Jiang B, Cobzas D, Huang C

Frontiers in neuroscience2022First author

DOI: 10.3389/fnins.2022.826316 PMID: 35360172

08

Predictive variables for peripheral neuropathy in treated HIV type 1 infection revealed by machine learning.

Tu W, Johnson E, Fujiwara E, Gill MJ, Kong L, Power C

AIDS (London, England)2021First author

DOI: 10.1097/qad.0000000000002955 PMID: 34033588

Statistical Learning and Inference for Sparse and Heterogeneous Functional and Longitudinal Data

Principal investigatorNSERC2023Discovery Grants Program - Individual

Principal investigators: Tu, Wei

Keywords: functional data analysis; functional regression; robust statistic; missing data; cancer clinical trials; quality of life; censored data; biostatistics

$54,000

Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative (Radio)Therapy: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)

Co-investigatorCIHR2023Project Grant

Principal investigators: Parulekar, Wendy R; Poon, Ian

Keywords: Head And Neck Cancer; Quality Of Life; Radiation Therapy; Randomized Phase Iii Trial; Stereotactic Body Radiation Therapy (Sbrt)

$1,602,675

Statistical Learning and Inference for Sparse and Heterogeneous Functional and Longitudinal Data

Principal investigatorNSERC2023Discovery Launch Supplement

Principal investigators: Tu, Wei

$12,500

The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.

Co-investigatorCIHR2023Project Grant

Principal investigators: Hay, Annette; Bramson, Jonathan L; Delisle, Jean-Sébastien; Leblanc, Richard; Quizi, Jennifer L

Keywords: Biomanufacturing; Cancer; Cell Therapy; Clinical Trial; First-In-Human; Immunotherapy; Multiple Myeloma; Relapsed And Refractory; Synthetic Androgen Receptor

$3,056,176

A Liquid-Biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-Inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Co-investigatorCIHR2022Project Grant

Principal investigators: Rushton-Marovac, Moira K; Cescon, David W; Seymour, Lesley

Keywords: Aromatase Inhibitor And Cdk4/6 Inhibitor Resistance; Biomarker; Circulating Tumour Cells (Ctcs); Circulating Tumour Dna (Ctdna); Hormone-Positive Metastatic Breast Cancer; Liquid Biopsy; Platform Trial; Umbrella Trial

$2,184,076

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Sebastien Hotte and Holger Hirte: 77 shared papers
Lesley Seymour and Dongsheng Tu: 20 shared papers
Ming-Sound Tsao and Lesley Seymour: 16 shared papers
John Goffin and Ming-Sound Tsao: 14 shared papers
Christopher Power and Esther Fujiwara: 14 shared papers
John Goffin and Dongsheng Tu: 13 shared papers
Linglong Kong and Bei Jiang: 12 shared papers
John Goffin and Lesley Seymour: 9 shared papers
Derek Jonker and Dongsheng Tu: 8 shared papers
Ming-Sound Tsao and Paul Wheatley-Price: 7 shared papers
Courtney Heather Coschi and Lesley Seymour: 6 shared papers
Sebastien Hotte and Ming-Sound Tsao: 5 shared papers
John Goffin and Paul Wheatley-Price: 5 shared papers
Sebastien Hotte and Lesley Seymour: 4 shared papers
Courtney Heather Coschi and Dongsheng Tu: 4 shared papers
Christopher Power and Linglong Kong: 4 shared papers
Janet Dancey and Lesley Seymour: 4 shared papers
Janet Dancey and Dongsheng Tu: 4 shared papers
Paul Wheatley-Price and Dongsheng Tu: 4 shared papers
John Goffin and Courtney Heather Coschi: 3 shared papers
John Goffin and Wei Tu: 3 shared papers
Holger Hirte and Stephanie Lheureux: 3 shared papers
Ming-Sound Tsao and Wei Tu: 3 shared papers
Lesley Seymour and John Hilton: 3 shared papers
Lesley Seymour and Wei Tu: 3 shared papers
John Hilton and Dongsheng Tu: 3 shared papers
Dongsheng Tu and Wei Tu: 3 shared papers
Sebastien Hotte and Anna Tinker: 2 shared papers
Sebastien Hotte and John Hilton: 2 shared papers
Courtney Heather Coschi and Wei Tu: 2 shared papers
Holger Hirte and Ming-Sound Tsao: 2 shared papers
Ming-Sound Tsao and Stephanie Lheureux: 2 shared papers
Janet Dancey and Wei Tu: 2 shared papers
Lesley Seymour and Derek Jonker: 2 shared papers
Stephanie Lheureux and Dongsheng Tu: 2 shared papers
Derek Jonker and John Hilton: 2 shared papers
Paul Wheatley-Price and Wei Tu: 2 shared papers
Linglong Kong and Dana Cobzas: 2 shared papers
Sebastien Hotte and Wei Tu: 1 shared paper
Holger Hirte and Anna Tinker: 1 shared paper
Holger Hirte and Wei Tu: 1 shared paper
Christopher Power and Bei Jiang: 1 shared paper
Christopher Power and Wei Tu: 1 shared paper
Esther Fujiwara and Linglong Kong: 1 shared paper
Esther Fujiwara and Wei Tu: 1 shared paper
Michael Mckenzie and Monnica Williams: 1 shared paper
Michael Mckenzie and Wei Tu: 1 shared paper
Janet Dancey and Anna Tinker: 1 shared paper
Monnica Williams and Wei Tu: 1 shared paper
Anna Tinker and Wei Tu: 1 shared paper
Stephanie Lheureux and Wei Tu: 1 shared paper
Derek Jonker and Wei Tu: 1 shared paper
John Hilton and Wei Tu: 1 shared paper
Linglong Kong and Wei Tu: 1 shared paper
Bei Jiang and Dana Cobzas: 1 shared paper
Bei Jiang and Wei Tu: 1 shared paper
Dana Cobzas and Wei Tu: 1 shared paper

Oncology
Department of Medicine
Public Health Sciences
Department of Laboratory Medicine and Pathobiology
Obstetrics and Gynecology
Department of Mathematical and Statistical Sciences
Medicine/Neurology
Other

1 shared papers, latest 2025

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their NSERC grant from 2023

Subject: Prospective PhD student: biostatistics Dear Professor Tu, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your NSERC-funded project "Statistical Learning and Inference for Sparse and Heterogeneous Functional and Longitudinal Data" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]